Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA® (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn ...

WASHINGTON — Vonoprazan effectively relieved heartburn symptoms in patients with nonerosive reflux disease as early as day 1 of treatment, with results persisting after a 4-week placebo ...

A triple therapy of vonoprazan, amoxicillin and bismuth potassium citrate achieved an eradication rate of just over 90%, similar to that of the standard quadruple therapy, in patients with ...

Vonoprazan Just as Good or Better Than Lansoprazole for Erosive Esophagitis — Randomized trial shows noninferiority for healing and superiority for maintaining healing ...

Vonoprazan was noninferior and superior to the PPI lansoprazole in healing and maintenance of healing of erosive esophagitis. This benefit was seen predominantly in more severe erosive esophagitis.

Currently, more than 20 million patients are afflicted with erosive esophagitis. The FDA action carries particular significance because it is the first major innovation for the condition in the past ...

The oral potassium-competitive acid blocker vonoprazan was noninferior and superior to the proton pump inhibitor lansoprazole for erosive esophagitis in a phase 3 trial.

Phathom Pharmaceuticals' vonoprazan (Voquenza) sets a new standard in erosive gastroesophageal reflux disease (GERD) therapy.

"Today marks an important step forward for Phathom Pharmaceuticals as we announce the FDA's acceptance for filing of our New Drug Application for VOQUEZNA as a daily treatment of heartburn for ...

Vonoprazan was associated with a greater percentage of 24-hour heartburn free days in patients with nonerosive gastroesophageal reflux disease.

We suggest, however, that a different mechanism may underlie much of the therapeutic action of rituximab in autoimmune diseases: binding of tens of thousands of rituximab−IgG molecules to B ...

“We are thrilled to announce the commercial availability of our first-in-class medication, VOQUEZNA, now available for the millions of people in the U.S. suffering from Erosive GERD,” said ...